The estimated Net Worth of Kenneth A. Lock is at least $1.55 millió dollars as of 6 March 2023. Mr. Lock owns over 831 units of Arcutis Biotherapeutics Inc stock worth over $667,273 and over the last 5 years he sold ARQT stock worth over $116,217. In addition, he makes $766,075 as Chief Commercial Officer at Arcutis Biotherapeutics Inc.
Sign up
Mr. Lock ARQT stock SEC Form 4 insiders trading
Kenneth has made over 8 trades of the Arcutis Biotherapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 831 units of ARQT stock worth $12,681 on 6 March 2023.
The largest trade he's ever made was exercising 7,500 units of Arcutis Biotherapeutics Inc stock on 15 October 2020 worth over $48,900. On average, Kenneth trades about 1,723 units every 79 days since 2020. As of 6 March 2023 he still owns at least 63,429 units of Arcutis Biotherapeutics Inc stock.
You can see the complete history of Mr. Lock stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kenneth Lock biography
Kenneth A. Lock serves as Chief Commercial Officer of the Company. He served as the Executive Director of Sales and Marketing at Gilead Sciences, concurrently leading the Inflammation and Pulmonary Hypertension U.S. commercial franchises from December 2013 to August 2019. Prior to Gilead, Mr. Lock was employed at Amgen, Inc. from March 2007 to November 2013, where he was involved in the prelaunch global development of Repatha for hyperlipidemia and also held U.S. brand marketing and sales leadership roles for Enbrel for Rheumatoid Arthritis and Psoriasis. From June 2003 to February 2007, Mr. Lock was at Wyeth Pharmaceuticals where he held various positions including Strategic Planning, International Commercial Operations, and Marketing for Enbrel in both Rheumatology and Dermatology. He started his career in process development and biologics manufacturing at IDEC Pharmaceuticals in 1996. Mr. Lock received both his B.S in Biochemistry / Cell Biology and B.A. in Psychology from University of California, San Diego and completed his M.B.A at Cornell University.
What is the salary of Kenneth Lock?
As the Chief Commercial Officer of Arcutis Biotherapeutics Inc, the total compensation of Kenneth Lock at Arcutis Biotherapeutics Inc is $766,075. There are 1 executives at Arcutis Biotherapeutics Inc getting paid more, with Todd Watanabe having the highest compensation of $1,140,300.
How old is Kenneth Lock?
Kenneth Lock is 46, he's been the Chief Commercial Officer of Arcutis Biotherapeutics Inc since 2019. There are 24 older and 4 younger executives at Arcutis Biotherapeutics Inc. The oldest executive at Arcutis Biotherapeutics Inc is Howard Welgus, 68, who is the Director.
What's Kenneth Lock's mailing address?
Kenneth's mailing address filed with the SEC is C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE, CA, 91361.
Insiders trading at Arcutis Biotherapeutics Inc
Over the last 5 years, insiders at Arcutis Biotherapeutics Inc have traded over $33,184,604 worth of Arcutis Biotherapeutics Inc stock and bought 3,754,945 units worth $71,202,175 . The most active insiders traders include Jonathan Silverstein, Patrick J Heron és Advisors Llcorbimed Capital.... On average, Arcutis Biotherapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $361,425. The most recent stock trade was executed by Howard G. Welgus on 3 September 2024, trading 10,000 units of ARQT stock currently worth $107,700.
What does Arcutis Biotherapeutics Inc do?
arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.
What does Arcutis Biotherapeutics Inc's logo look like?
Complete history of Mr. Lock stock trades at Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics Inc executives and stock owners
Arcutis Biotherapeutics Inc executives and other stock owners filed with the SEC include:
-
Todd Watanabe,
President, Chief Executive Officer, Director -
Kenneth Lock,
Chief Commercial Officer -
Todd Franklin Watanabe M.A.,
Pres, CEO & Director -
Patricia Turney,
Senior Vice President - Manufacturing -
Dr. Patrick E. Burnett M.D., Ph.D.,
Sr. VP & Chief Medical Officer -
Kenneth A. Lock,
Chief Commercial Officer -
Bhaskar Chaudhuri,
Independent Director -
Joseph Turner,
Independent Director -
Ricky Sun,
Independent Director -
Jonathan Silverstein,
Independent Director -
Howard Welgus,
Director -
Halley Gilbert,
Director -
Terrie Curran,
Director -
Patrick Burnett,
Chief Medical Officer -
Keith Klein,
General Counsel -
Frank Pompilio,
Vice President - Medical Affairs -
Lynn Navale,
Vice President - Biometrics -
Charlotte Merritt,
Vice President - Regulatory Affairs -
Ayisha Jeter,
Vice President of Market Access -
Meg Elias,
Vice President - Clinical Operations -
Bethany Dudek,
Vice President - Quality -
David Berk,
Vice President - Clinical Development -
Heather Armstrong,
Vice President of Investor Relations and Corporate Communications -
Kimberly Lathroum,
Vice President of Marketing -
Jay Ramsinghani,
Vice President of Commercial Strategy and Operations -
Scott Burrows,
Vice President - Finance -
John Smither,
Chief Financial Officer -
David Osborne,
Co-Founder, Chief Technical Officer -
Patrick Heron,
Independent Chairman of the Board -
Masaru Matsuda Esq., J.D.,
Gen. Counsel & Corp. Sec. -
Courtney Barton,
Chief Compliance Officer, VP, Chief of Staff & Chief Privacy Officer -
Eric McIntyre,
Head of Investor Relations -
Dr. David W. Osborne,
Chief Technical Officer -
Patricia A. Turney,
Sr. VP of Operations -
Scott L. Burrows,
CFO & Principal Accounting Officer -
Larry Todd Edwards,
SVP Chief Commercial Officer -
Daniel Estes,
Director -
Neha Krishnamohan,
Director -
David Joseph Topper,
Chief Financial Officer -
Masaru Matsuda,
See Remarks -
Capital Life Sciences Inves...,
-
Advisors Llcorbimed Capital...,
-
Life Sciences Viii, L.P.Fhm...,
-
Matthew Richard Moore,
SVP and Chief Business Officer -
Life Sciences Viii, L.P.Fhm...,
-
Sue Jean Lin,
Director -
Keith R Leonard,
Director -
Life Sciences Viii, L.P.Fhm...,